Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders

This study has been terminated.
(Poor accrual)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: July 26, 2006
Last updated: January 25, 2012
Last verified: January 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2011
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)